Mega Biopharma

Mega Biopharma is a private, clinical-stage biotech company pioneering a disruptive biomaterial platform based on nacre (mother-of-pearl). Its lead product, the Bionacre® Bone Graft, is positioned as a bioactive, fully resorbable graft for managing bone voids in dental and orthopedic applications, meeting key criteria for an ideal graft substitute. The company has achieved ISO 9001 certification and recently secured €7.5M in Pre-Series A funding, with a Series A round targeting €15M to propel growth. Mega Biopharma operates in the large and growing global bone graft substitute market, aiming to establish a new standard of care.

Patented Bionacre® technology that processes pure, bioactive nacre (mother-of-pearl) into a dual-matrix biomaterial. The platform yields a graft with combined osteoconductive (ceramic scaffold) and osteoinductive (organic bioactive molecules) properties, featuring optimized, kinetic resorbability.

The bone graft market is crowded with synthetic ceramics (e.g., β-TCP, hydroxyapatite), demineralized bone matrices (DBM), and allografts. Mega Biopharma competes by offering a unique natural material (nacre) that combines osteoconduction, osteoinduction, and controlled resorption—a combination that few existing products claim to achieve simultaneously.